Professor Terry Rabbitts is currently a Professor of Immunology at the Institute of Cancer Research in London (UK), where he focuses on developing technologies using intracellular antibody fragments and small molecule derivatives, mainly aimed at targeting chromosomal translocation protein products. Terry is the ex-Chair of Cambridge Antibody Technology’s Scientific Advisory Board from launch until it’s IPO and is currently an advisor to several start-up biotech companies, as well as a co-founder of both Orbit Discovery and Quadrucept Bio Ltd.​